Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,304.00
Ask: 12,600.00
Change: 0.00 (0.00%)
Spread: 296.00 (2.406%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK PM reassures over AstraZeneca jab as under-30s offered alternative

Thu, 08th Apr 2021 06:34

(Alliance News) - Prime Minister Boris Johnson has sought to reassure the public the Oxford/AstraZeneca PLC vaccine is safe after UK regulators said there was a possible link between the jab and "extremely rare" blood clots.

The Medicines & Healthcare products Regulatory Agency said the benefits still outweigh the risks overall but while it has not concluded that the vaccine causes rare brain clots, it said the link is getting firmer.

Regulators have recommended that people aged 18 to 29 should be offered the Pfizer, Moderna or other vaccines that come on stream as the programme continues to rollout across the UK.

It comes as the family of a solicitor who died from a blood clot after receiving an AstraZeneca vaccine urged the public to "keep saving lives" by taking up a jab when offered it.

The prime minister sought to boost public confidence in the Oxford-developed shot as he said the changes in its use would not force a change in the road map out of lockdown.

Johnson told reporters in Cornwall: "These vaccines are safe, they've saved many thousands of lives and people should come forward to get their jabs and we'll make sure that they get the right jabs."

MHRA's chief executive Dr June Raine told a press conference that there was a "reasonably plausible" link between the AstraZeneca jab and rare blood clots, but stressed these were "extremely rare".

She said: "Based on the current evidence, the benefits of the Covid-19 vaccine AstraZeneca against Covid-19 and its associated risks – hospitalisation and death – continues to outweigh the risks for the vast majority of people.

"Our review has reinforced that the risk of this rare suspected side effect remains extremely small."

Meanwhile the family of Neil Astles, 59, who died in hospital on Easter Sunday after receiving his first AstraZeneca jab dose on March 17, told the Telegraph that they wanted the public to continue taking up the vaccine.

Dr Alison Astles told the newspaper: "If we all have the vaccine, a few of us might have a blood clot but the evidence is that fewer people will die.

"We trust the process, we trust the regulator, and despite what has happened to our family, we don't want people to be scared off. That's the message we want to get across."

A separate review by the European Medicines Agency (EMA) concluded on Wednesday that "unusual blood clots with low blood platelets should be listed as very rare side effects" of the AstraZeneca vaccine.

The MHRA said that up to March 31, across the UK it had received 79 reports of blood clots accompanied by low blood platelet count, all in people who had their first dose of the vaccine, out of around 20 million doses given.

Of these 79, a total of 19 people have died, the regulator said, although it has not been established what the cause was in every case. Of the 19 who died, three were under the age of 30.

The figures suggest the risk of rare blood clot is the equivalent to four people out of every million who receive the vaccine.

The MHRA said that those who have had their first dose of the AstraZeneca vaccine should still get their second dose.

Only those who suffered a rare blood clot after the first dose should not get vaccinated.

Anyone with blood disorders that leave them at risk of clotting should discuss the benefits and risks of vaccination with their doctor before going for a jab.

In Europe, the EMA has carried out an in-depth review of 62 cases of cerebral venous sinus thrombosis and 24 cases of splanchnic vein thrombosis, in which 18 people died.

Health Secretary Matt Hancock said on Twitter that the findings by the MHRA and EMA had confirmed that the AstraZeneca jab was "safe" and that the benefits of the jab "far outweigh the risks for the vast majority of adults".

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.